Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Amarin Corporation plc is a biotechnology business based in the US. Amarin Corporation shares (AMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Amarin Corporation employs 965 staff and has a trailing 12-month revenue of around USD$546 million.
|52-week range||USD$3.36 - USD$24.67|
|50-day moving average||USD$5.7091|
|200-day moving average||USD$7.1299|
|Wall St. target price||USD$11.1|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.266|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-17)||-100.00%|
|1 month (2020-08-27)||-100.00%|
|3 months (2020-06-26)||-100.00%|
|6 months (2020-03-27)||-100.00%|
|1 year (2019-09-27)||-100.00%|
|2 years (2018-09-27)||-100.00%|
|3 years (2017-09-27)||-100.00%|
|5 years (2015-09-25)||-100.00%|
|Revenue TTM||USD$546 million|
|Gross profit TTM||USD$333.7 million|
|Return on assets TTM||-1.81%|
|Return on equity TTM||-3.33%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 26.4 million Amarin Corporation shares held short by investors – that's known as Amarin Corporation's "short interest". This figure is 5% down from 27.8 million last month.
There are a few different ways that this level of interest in shorting Amarin Corporation shares can be evaluated.
Amarin Corporation's "short interest ratio" (SIR) is the quantity of Amarin Corporation shares currently shorted divided by the average quantity of Amarin Corporation shares traded daily (recently around 6.3 million). Amarin Corporation's SIR currently stands at 4.17. In other words for every 100,000 Amarin Corporation shares traded daily on the market, roughly 4170 shares are currently held short.
However Amarin Corporation's short interest can also be evaluated against the total number of Amarin Corporation shares, or, against the total number of tradable Amarin Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amarin Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Amarin Corporation shares in existence, roughly 70 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Amarin Corporation shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amarin Corporation.
Find out more about how you can short Amarin Corporation stock.
We're not expecting Amarin Corporation to pay a dividend over the next 12 months.
Amarin Corporation's shares were split on a 1:10 basis on 18 January 2008. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amarin Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Amarin Corporation shares which in turn could have impacted Amarin Corporation's share price.
Over the last 12 months, Amarin Corporation's shares have ranged in value from as little as $3.36 up to $24.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amarin Corporation's is 2.66. This would suggest that Amarin Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.